MTOR and mesothelioma: To date, mTOR inhibitors have been investigated, and an allosteric mTOR inhibitor, rapamycin, has been demonstrated to have selective growth inhibitory effects in NF2-deficient mesothelioma cells (Lopez-Lago et al., 2009).